Comment to “Deep Vein Thrombosis Induced by Vasculitis in the Behçet’s Syndrome”
Behçet’s syndrome (BS) is a rare, systemic vasculitis of unknown etiology that can affect multiple organ systems, including the skin, mucosa, joints, eyes, vascular system, nervous system, and gastrointestinal tract. The syndrome is characterized by recurrent oral and genital ulcers, uveitis, and skin lesions, but its systemic nature means that it can also lead to severe complications such as deep vein thrombosis (DVT), arterial aneurysms, and gastrointestinal perforations. The case reported by Chen and Guan highlights the complexities of managing BS, particularly when it is complicated by DVT and potential gastrointestinal involvement. This commentary aims to address the key issues raised by the case, focusing on the use of anticoagulants and immunosuppressive therapy in BS patients, as well as the management of gastrointestinal involvement in the syndrome.
Behçet’s Syndrome and Deep Vein Thrombosis
BS is a systemic vasculitis that can lead to both arterial and venous complications. DVT is one of the most common venous manifestations of BS, and it is thought to result from inflammation rather than hypercoagulability. The inflammation in BS leads to endothelial damage, which in turn predisposes patients to thrombus formation. The case reported by Chen and Guan involved a 37-year-old male with a 5-year history of BS who developed DVT. The patient’s condition worsened after his warfarin was discontinued for 7 days, leading to upper abdominal pain, chest pain, dyspnea, and ultimately cardiac arrest. Despite resuscitation efforts, the patient died within an hour.
The management of DVT in BS patients is complex and often requires a combination of anticoagulants and immunosuppressive therapy. While anticoagulants are commonly used to treat DVT, their role in BS is less clear. A meta-analysis of three retrospective studies indicated that adding anticoagulants to immunosuppressive therapy did not reduce the risk of relapse in BS patients with DVT. However, the lack of prospective controlled trials means that no definitive recommendations against the use of anticoagulants can be made. In cases where DVT is refractory to treatment, anticoagulation may still be considered to reduce the risk of pulmonary embolism, provided that arterial aneurysms have been ruled out. This is particularly important because almost all BS patients with aneurysms have a history of DVT, and anticoagulation in these patients can increase the risk of bleeding.
The authors of the case report noted that no revisited guidelines for the treatment of BS were made. However, the 2018 update of the EULAR recommendations for the management of BS provides some guidance. According to these recommendations, glucocorticoids and immunosuppressive agents such as azathioprine, cyclophosphamide, or cyclosporine A are recommended for the management of acute DVT in BS. Monoclonal anti-TNF antibodies may also be considered in patients with refractory venous thrombosis, as they have shown beneficial results in BS patients with refractory arterial involvement.
Immunosuppressive Therapy in Behçet’s Syndrome
Immunosuppressive therapy is a cornerstone of treatment for BS, particularly during acute attacks. Rapid immunosuppressive treatment can help reduce the relapse rate of venous thrombosis when compared to anticoagulant therapy alone. In the case reported by Chen and Guan, the patient initially responded well to immunosuppressive therapy, but his condition deteriorated rapidly on the 7th day of hospitalization. This suggests that the immunosuppressive therapy used in this case was not sufficient to control the disease.
The updated EULAR guidelines recommend the use of glucocorticoids and immunosuppressive agents such as azathioprine, cyclophosphamide, or cyclosporine A for the management of acute DVT in BS. However, there is no data to guide the management of patients with refractory venous thrombosis. Monoclonal anti-TNF antibodies may be considered in these patients, as they have shown beneficial results in BS patients with refractory arterial involvement. Further clinical studies are needed to determine the optimal immunosuppressive regimen for BS patients with refractory venous thrombosis.
Gastrointestinal Involvement in Behçet’s Syndrome
Gastrointestinal involvement in BS (GIBS) is relatively common, with the most frequent sites of involvement being the colon and the ileocecal region. The reported frequency of GIBS varies widely, ranging from 3% to 60%. Gastrointestinal complications in BS can be severe and include perforation and massive bleeding, which are often the result of vasculitis. During acute exacerbations of GIBS, glucocorticoids should be considered to promote the rapid healing of ulcers, together with 5-aminosalicylate (5-ASA) or azathioprine. In refractory cases, monoclonal anti-TNF antibodies and/or thalidomide may be considered.
A cohort study of GIBS patients showed that almost a third of these patients required emergency surgery due to perforation or major bleeding. Timely recognition of these complications is crucial, as they can be fatal if left untreated. In the case reported by Chen and Guan, the patient developed upper abdominal pain after his warfarin was discontinued, and urgent abdominal computed tomography revealed multiple microstones in the left kidney. However, no other abnormalities were detected. The patient’s symptoms recurred the following morning, leading to chest pain, dyspnea, and cardiac arrest.
Given the patient’s symptoms and the known complications of GIBS, it is highly likely that the patient also suffered from GIBS. In such cases, 5-ASA or azathioprine should be considered as part of the treatment regimen, rather than relying solely on indomethacin administered per rectum. If the patient’s symptoms are not relieved, urgent surgery should be considered. Additionally, Budd-Chiari syndrome (BCS) cannot be completely excluded in this case, and further diagnostic tests may be warranted.
Conclusion
The case reported by Chen and Guan highlights the complexities of managing BS, particularly when it is complicated by DVT and potential gastrointestinal involvement. The management of DVT in BS patients often requires a combination of anticoagulants and immunosuppressive therapy, but the role of anticoagulants in BS is not well-defined. Immunosuppressive therapy is a cornerstone of treatment for BS, particularly during acute attacks, but further clinical studies are needed to determine the optimal regimen for patients with refractory venous thrombosis. Gastrointestinal involvement in BS can be severe and requires timely recognition and treatment to prevent fatal complications.
BS is a rare and frequently underdiagnosed condition, and prospective controlled clinical trials are of considerable importance to improve our understanding of the syndrome and its management. The 2018 update of the EULAR recommendations for the management of BS provides some guidance, but further research is needed to refine these recommendations and improve outcomes for BS patients.
doi.org/10.1097/CM9.0000000000000120
Was this helpful?
0 / 0